Ann: Orthocell Webinar Presentation, page-4

My notes from the webinar:

• No US Tarrif impact expected.

- we have deep defence ties
- AU has Trade Deficit with USA.

• Effect of DOGE on FDA efficiency and approvals:

- No imopact as most the staff has been retained by FDA
- Regular and Positive interactions with FDA
- Our Lead Reviewer remains teh same at FDA
- US approval ETA for Remplir remians on track for Mar/Apr 2025

• 3 Consecutive qurters if record revenue

- 9% CAGR of quarterly revenue since launch of Remplir

• Crendentialed board with ties and experience in US market

• Tendon product SmartGraft scaffold) expected to launch in AU in CY25

• REMPLIR

- 127% revenue growth in AU from FY 23($457k) to FY24($1.04M)
- US TAM: USD$1.6B
- 700,000 nerve repair surgerical procedure done in US annualy. Most are suturing and 55% of them are unsuccessful.

• Expected REMPLIR Approvalsapplications already submitted)

- US: Q1 25
- Thailand: Q3 25
- Canada: Q4 25


*Total TAM (markets planned to enter): U$3.5B
Aim to achieve at least 20% i.e. U$700k or AUD$1B

**No questions taken.